Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
Official source
ZELBORAF: baseline renal function and renal-toxicity monitoring
This source only - not a merged recommendation
What matters first
Product: Adult oral ZELBORAF for its labeled oncology indications; this is not a complete oncology regimen.
Renal action / finding
Mild/moderate: no renal adjustment. Severe: dose not established.
Evidence or dialysis limit
No HD or CRRT regimen established in these passages.
Monitoring / application
Monitor creatinine; baseline dosing does not remove nephrotoxicity risk.
Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.
Product / population
Adult oral ZELBORAF for its labeled oncology indications; this is not a complete oncology regimen.
Renal measure
Mild/moderate/severe renal categories; CrCl in mL/min in the supporting PK analysis
Source revision
07/2026
Retrieved
2026-11-07 (not the revision date)
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
No HD or CRRT regimen established in these passages.
Sections 8.7, 12.3 and 5.11
Sections 8.7, 12.3 and 5.11
Situation
Source-specific guidance
Mild or moderate impairment
No renal dose adjustment recommended.
Severe impairment
Appropriate dose not established.
Renal toxicity
Creatinine before treatment and periodically.
Read the retained text before reformatting
Population pharmacokinetics support no dose adjustment for mild or moderate impairment. There was no formal renal-impairment study; the appropriate dose in severe impairment is not established. Renal failure, including interstitial nephritis and tubular necrosis, has been reported. Check serum creatinine before treatment and periodically. These passages do not establish a hemodialysis or CRRT regimen.
Source revision: 07/2026 | Retrieved: 2026-11-07. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-specific interpretation
What the dialysis evidence actually supports
Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.
ZELBORAF: baseline renal function and renal-toxicity monitoring
Source retrieved 2026-11-07 - confirm current applicability
No dialysis regimen established in selected content
These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
Source scope / renal recommendation differences
Renal category guidance is not severe-impairment or dialysis validation
The label and its mirror describe the same category-based limitation. The mirror is not a second independent clinical recommendation.
How to use this: Use the exact label and monitor kidney toxicity; seek specialist guidance for severe impairment or dialysis.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source
ZELBORAF: baseline renal function and renal-toxicity monitoring
Adult oral ZELBORAF for its labeled oncology indications; this is not a complete oncology regimen.
Method: Mild/moderate/severe renal categories; CrCl in mL/min in the supporting PK analysis
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Important source distinctions
An RX mirror and its underlying label are not independent clinical confirmations.
DailyMed / product prescribing information · Adult oral ZELBORAF for its labeled oncology indications; this is not a complete oncology regimen.
Renal method: Mild/moderate/severe renal categories; CrCl in mL/min in the supporting PK analysis Source date: 07/2026 Retrieved: 2026-11-07
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
No HD or CRRT regimen established in these passages.
Dialysis evidence: No dialysis regimen established in selected content
Selected named sections summarized; not a complete monograph or independent clinician approval.
Sections 8.7, 12.3 and 5.11
Sections 8.7, 12.3 and 5.11
Situation
Source-specific guidance
Mild or moderate impairment
No renal dose adjustment recommended.
Severe impairment
Appropriate dose not established.
Renal toxicity
Creatinine before treatment and periodically.
Read the retained text before reformatting
Population pharmacokinetics support no dose adjustment for mild or moderate impairment. There was no formal renal-impairment study; the appropriate dose in severe impairment is not established. Renal failure, including interstitial nephritis and tubular necrosis, has been reported. Check serum creatinine before treatment and periodically. These passages do not establish a hemodialysis or CRRT regimen.
RDM71-vemurafenib-zelboraf-label-1 · Source locator: Sections 8.7, 12.3 and 5.11
GlobalRPh RX List / label mirror · Adult oral ZELBORAF for its labeled oncology indications; this is not a complete oncology regimen.
Renal method: Renal impairment categories; see underlying label Source date: Not established in reviewed passage Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
Confirm product, indication, renal measure and dialysis modality before applying.
Dialysis evidence: No dialysis regimen established in selected content
Selected named sections summarized; not a complete monograph or independent clinician approval.
Selected renal sections
The mirror describes no adjustment for mild or moderate renal impairment and an undefined appropriate dose for severe impairment. Its population-PK rationale does not establish dialysis dosing. This mirror is not independent validation of the label.
Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.
